Coix (Coix lacryma-jobi L.): A Comprehensive Reference
1. Identity, Taxonomy, and Common Names
Coix lacryma-jobi L. is a member of the Gramineae (Poaceae) family, bearing the common English names adlay, coix, and Job's tears. The botanical name derives its common English name from the distinctive teardrop shape of its seeds, which are technically hardened, bead-like false fruits or utricles. In Traditional Chinese Medicine (TCM), the plant is most commonly known as Yi Yi Ren (薏苡仁), and its dried, mature seeds are referred to as Coicis Semen.
Coicis Semen is derived from the dried and mature seeds of Coix lacryma-jobi L. var. ma-yuen (Roman.) Stapf. There are four different varieties of coix: C. lacryma-jobi var. ma-yuen (Rom. Caill.) Stapf., C. lacryma-jobi var. Puellarum (Balansa), C. lacryma-jobi var. lacryma-jobi, and C. lacryma-jobi var. stenocarpa Oliv. Of these, the cultivated variety Coix lacryma-jobi var. ma-yuen is harvested as a cereal crop, has a soft shell, and is used in traditional medicine in parts of Asia.
The crop may also be referred to under different spellings (Job's-tears, Jobs-tears) and is known by other common names in English, such as adlay or adlay millet, coix seed, gromwell grass, and tear grass. In Japanese medicine (Kampo), the seed is called hatomugi.
Botanical Description
Coix lacryma-jobi is an upright, robust, perennial (often cultivated as an annual) grass that typically grows to a height of 1 to 3 meters. The leaf blades are long, broad, and narrowly lanceolate, measuring 20–50 cm in length and 1.5–4 cm in width, with a prominent pale midrib running along the blade and a short membranous ligule at the base. Job's tears is monoecious, producing separate male and female flowers on the same plant.
The seeds are pear-shaped with a shiny, dark brown to gray-black hull. Like other members of the grass family, coix has seeds containing prolamin as the major storage protein, known as coixin, which represents more than 70% of the endosperm protein.
Geographic Origin and Distribution
The genus Coix is believed to have originated in the hilly tracts of Northeastern India and Myanmar, a region characterized by remarkable genetic diversity of wild Coix lacryma-jobi and Coix aquatica. Job's tears—a cultigen of great antiquity—is grown in South Asia mainly by the natives of various ethnic groups of Mongolian origin. Thousands of years before European traders brought maize to the Far East, Job's tears was already grown across Southern, Southeast, and Eastern Asia. Today, Coix lacryma-jobi is widely cultivated in China and Japan as a nutritious food supplement.
Common Preparations and Forms
It has been widely consumed in forms such as porridge, beverages, and as a rice substitute, while also being used therapeutically for wounds, urinary tract infections, and inflammatory disorders. Coix grain is generally polished as hulled grain or milled as flour and used in food components. In China, coix seeds are used in soups and beverages. Job's tears is also fermented into beer.
From a medicinal standpoint, coix is administered as a dried seed kernel for decoction, as an extract in capsule form, and most notably as an injectable oil preparation. Kanglaite (KLT), a Chinese medicine preparation widely used in China to treat lung and liver cancer or complications of cancers, is available as injections and capsules, and is mainly composed of the oil extracted from coix seeds.
2. Traditional and Historical Use
Traditional Chinese Medicine
Coix was first mentioned in the Shennong Bencao Jing (ca. 100 A.D.), mainly for use in treating people with stiffness attributed to inability to contract or stretch the sinews and for "bi syndrome" due to wind-damp. The Shennong Bencao Jing is a Chinese book on agriculture and medicinal plants, traditionally attributed to Shennong, and researchers believe the text is a compilation of oral traditions written between the first and second centuries AD. The Shennong Bencao Jing, the earliest specialized herbal medicinal book in China, documents 59 types of dual-purpose materials as medicine and food, including coix seeds.
Documented in the ancient Shennong Bencao Jing as a top-grade remedy, coix was praised for its sweet, slightly cold nature and ability to treat muscle spasms, joint pain, rheumatism, and edema. In the Jingui Yaolue (ca. 200 A.D.), the combination of coix and aconite was one of the recommended treatments for a syndrome of "thoracic paralysis." The use of coix for stiffness in the limbs is preserved to this day in Japanese Kampo practice with Yiyiren Tang (Coix Combination), first introduced by Huang Fuzhong in his book Mingyi Zhizhang (1502 A.D.) and brought to Japan during the major transfer of the Chinese herb system in the 16th and 17th centuries.
In traditional Chinese medicine, coix seeds serve several functions: they stimulate the function of the spleen and lung, remove heat (which helps in the drainage of pus), induce diuresis, and are used to treat the symptoms of diarrhea and arthritis. In more recent centuries, coix became better known as an herb for promoting diuresis in cases where moisture retention occurred secondary to impairment of the internal organs that circulate and eliminate moisture—the spleen, lungs, and kidney—with the main effect of the herb being on the spleen.
In TCM theory, coix seed has a sweet and light taste and a cool nature, and it enters the spleen, stomach, and lung meridians. Raw coix seed is cold in nature with strong diuretic and dampness-clearing effects, while stir-fried coix seed is milder and better suited to spleen support and diarrhea relief.
Traditionally, Chinese used coix cereal as medicinal food, tea, and herbal decoction to treat diabetes, inflammation, and neuralgia. Coix can also be used in TCM for flat warts on the skin, either as a water decoction of 1 tael or as a porridge of 2 taels, taken for about a month.
Japanese Kampo Medicine
Coix (Coix lacryma-jobi Linné var. mayuen Stapf), unlike many herbs used in Chinese traditional medicine, is often used as a single agent in Japan. The Kampo tradition inherited the formula Yiyiren Tang for musculoskeletal stiffness and rheumatic conditions, and Japanese research into coix has continued into the modern era, particularly concerning its effects on viral skin conditions.
South and Southeast Asian Ethnobotany
The northeastern region of India is a centre of variability for the genus Coix, where it is considered to have been introduced either by pastoral Aryan invaders who grew it on the slopes of the Himalayas, or during Mongolian conquests when the crop was distributed from the eastern Himalayas to lower subtropical terrains. Anthropologist Dr. Malcolm Cairns reports that Job's tears was traditionally grown by Naga farmers in northeast India to be fermented and also used in snacks and tea.
Archaeological evidence of coix has been recovered from two Han Dynasty tombs (dated to approximately 2,100 cal BP) in Xi'an, Shaanxi Province, China, where macrobotanical and phytolith analysis confirmed the remains as C. lacryma-jobi var. lacryma-jobi. The findings provide new insight into the cultural significance of Coix in Han Dynasty funerary customs.
Beyond food and medicine, the hard, white grains of Job's tears have historically been used as beads to make necklaces and other objects; the seeds are naturally bored with holes without the need for artificial puncturing, and strands of Job's tears are used as Buddhist prayer beads in parts of India, Myanmar, Laos, Taiwan, and Korea.
3. Key Constituents and Active Compounds
The chemical constituents of coix seed include various fatty acids, esters, polysaccharides, sterols, alkaloids, triterpenes, tocopherols, lactams, lignans, phenols, flavonoids, and other constituents. To date, more than 80 individual compounds have been isolated from this botanical.
Coixenolide
Active medicinal components of coix grain include coixol, coixin, and coixenolide, which have been the subject of considerable recent research. Coixenolide is a mixed glyceride of fatty acids and is the most extensively studied anti-tumor constituent. As early as 1961, the Japanese scholar Ukita and his colleagues first isolated coix seed ester from Coicis Semen and provided evidence of its anti-tumor effect. Kanglaite (KLT) injection is an extract from Coix lacryma-jobi (adlay) seed whose main active ingredient is a triglyceride containing four types of fatty acids.
The contents of coixenolide in coix seeds have been quantified at 176.77 ± 5.91 to 238.60 ± 0.21 μg/g, with phytosterol contents of 52.45 ± 2.05 to 58.23 ± 1.14 mg/g, and polysaccharides of 3.42 ± 0.10 to 4.41 ± 0.10 mg/g.
Coixol
Coixol (6-methoxybenzoxazolone), a pharmacologically active compound isolated from Coix lacryma-jobi L., has demonstrated central muscle relaxant properties. Adlay seeds contain physiologically active substances, including coixol, coixenolide, and lactams. Adlay sprouts reach their peak coixol content of 39.38 mg/g on the third day after sowing. Coixol has also attracted interest for its effects on skin pigmentation: an ethanolic extract at 1 mg/mL caused 48.4% inhibition of tyrosinase activity in B16F10 melanocytes and 50.7% on human tyrosinase (hTyr) fragment 369–377.
Polysaccharides (Coixans)
Coix seed is recognized as a functional medicinal food due to its valuable biological activities, with polysaccharides being the primary active compounds. Coicis Semen is rich in polysaccharides, including coixan A, B, and C, acidic polysaccharides CA-1 and CA-2, neutral glucans 1–7, and fructo-oligosaccharides. In coix seed, polysaccharides are the principal active components exhibiting anti-inflammatory, analgesic, and hypoglycemic activities.
Other Bioactive Compounds
Coix seeds contain phenols, flavonoids, polysaccharides, proteins, fibers, vitamins, and oils. Active ingredients retrieved from coix seed via network pharmacological analysis include sitosterol α1, mandenol, hexamethyltetracosahexaene, [(2R)-2,3-dihydroxypropyl] (Z)-octadec-9-enoate, sitosterol, stigmasterol, coixenolide, 2-monoolein, and cholesterol (CLR). Proteins, essential amino acids, and carbohydrates are found in coix seeds; additionally, important classes of bioactive compounds including coixenolide, triglyceride, fatty acids, and triterpenes have been found to provide numerous health benefits. Starch comprises the largest portion, ranging from 50% to 79% of the seed's dry weight. The seeds contain a significant amount of protein, typically 16–19%.
4. Mechanisms of Action
Anti-Tumor Mechanisms
Studies have shown that the fatty acids and esters in Coicis Semen can exert anti-tumor effects by inhibiting the proliferation and metastasis of tumor cells, preventing tumor angiogenesis, increasing the sensitivity to radiotherapy, and improving the body's immunity. At the molecular level, coix seed extract can regulate the expression of apoptotic proteins including wild-type p53, bcl-2, Fas, and caspase-3, and is also known to inhibit NF-κB-dependent transcription, which is recognized as a target for cancer therapy.
Hypoglycemic Mechanisms
Polysaccharides from coix seeds have a hypoglycemic effect and can improve diabetes complications in diabetic mice. PCR array analysis indicated upregulation of insulin signaling genes (GLUT4, IRS1, and PIK3R1) and downregulation of inflammatory markers (TNF and IL6) following treatment with coix extract. In cell-based research, coixol (200 μM) stimulated insulin secretion at high glucose concentration (20 mM) after incubation for 60 min at 37°C, which is consistent with a glucose-stimulated insulin secretion mechanism.
Anti-Inflammatory Mechanisms
Coix has strong chemical constituents to inhibit enzymes of cyclooxygenase (COX), fatty acid synthase, matrix metalloproteinases, and liver cholesterol synthesis. Coix seed constituents have demonstrated antioxidant, anti-inflammatory, anti-obesity activity, and modulation of gut microbiota.
Lipid Metabolism Mechanisms
Compared to other dietary fats, coix seed oil (CSO) treatment considerably lowered body weight and liver index, successfully suppressed total cholesterol and triglyceride content, and raised liver lipid deposition and lipid metabolism problems induced by high-fat intake in animal models. Results from animal studies showed that coix seed extract (CSE) notably improved liver pathological injury and oxidative stress, reduced levels of glucose and lipid in hyperlipidemia mice, and decreased lipid-related metabolites, with 16S rRNA sequencing revealing that CSE treatment notably increased the diversity of gut microbiota.
5. Scientific Evidence by Area of Use
5.1 Oncology (Anti-Tumor Effects)
Studies have confirmed that coix seed and its extract can reduce the proliferation, invasion, and migration of lung cancer, colon cancer, liver cancer, breast cancer, cervical cancer, gastric cancer, pancreatic cancer, and other cancers, and can promote their apoptosis. The most clinically advanced preparation is Kanglaite (KLT) injection. Kanglaite Injection is a neutral oil extracted and isolated from coix seed, recorded in many ancient Chinese medicinal books and compiled in editions of the Chinese Pharmacopoeia as a traditional medicine; it was approved in China in 1995 for the treatment of advanced non-small cell lung cancer and advanced hepatocellular carcinoma.
Non-Small Cell Lung Cancer (NSCLC): A meta-analysis evaluated the influence of Kanglaite injection combined with chemotherapy versus chemotherapy alone on clinical efficacy, immune function, and safety for the treatment of advanced NSCLC, with several databases including PubMed, Web of Science, EMBASE, and the Cochrane Library comprehensively searched from January 2000 to November 2019. Twenty-five RCTs comprising 2,151 patients meeting the inclusion criteria were identified; meta-analysis showed that KLTi plus the same chemotherapy significantly improved clinical efficacy—including complete response, partial response, stable disease, and progressive disease—as well as immune function indicators (CD3+, CD4+, CD8+, and CD4+/CD8+ ratios). There was a significant reduction in nausea and vomiting, thrombocytopenia, and leukopenia in combination treatments; however, the outcomes were limited because of the low quality and small sample size of the included studies. The authors concluded that more rigorous and well-designed RCTs are needed to confirm these findings.
Pancreatic Cancer: A phase 2b, multi-center, randomized, open-label clinical trial enrolled 85 patients: 53 received KLTi plus standard doses of gemcitabine, and 27 received gemcitabine alone; 41 patients were randomized into Cohort 1 (30 g/day KLTi). Cohort 2 (50 g/day) was terminated due to feasibility difficulties with enrollment and retention because of the long infusion time, and Cohort 3 (an additional 100 patients at 30 g/day) was stopped early following the FDA approval of Abraxane for late-stage pancreatic cancer. The trial was exploratory and inconclusive regarding efficacy.
Cancer Pain: A meta-analysis included a total of 18 randomized controlled trials involving 1,197 patients to evaluate KLT in managing cancer pain. The heterogeneity between the combined study results was quite high (I²=69%); using a random-effects model, the results showed [SMD = −1.24, 95% CI (−1.68, −0.80), P < 0.001], indicating a statistically significant difference, suggesting that Kanglaite Injection combined with chemotherapy improves pain severity scores compared to chemotherapy alone.
Overall Evidence Quality in Oncology: An evidence-mapping overview examined all published meta-analyses on KLT. Thirteen meta-analyses published in English were included for in-depth analysis; the years of publication ranged from 2008 to 2021, with numbers of included patients ranging from 488 to 2,964; seven articles focused on non-small cell lung cancer, two on malignant pleural effusion, and four on digestive system malignancies such as hepatocellular carcinoma and pancreatic cancer. Almost all included meta-analyses reported that KLT as adjunctive therapy could improve various efficacy outcomes (such as disease response rates, quality of life, and immune indicators) and reduce the rate of adverse reactions such as nausea and vomiting, leukopenia, and anemia. However, in terms of methodological quality, three meta-analyses were of low quality, whereas 10 studies were critically low in quality. This is a critical limitation: the clinical oncology evidence base for KLT/coix, while numerically large, is predominantly composed of studies conducted in China with significant methodological concerns, and the results cannot be considered conclusive by the standards of high-quality global clinical evidence.
5.2 Glycemic Control and Diabetes
Numerous studies have demonstrated that polysaccharides can modulate insulin resistance and improve insulin sensitivity; in coix seed specifically, polysaccharides are the principal active components exhibiting hypoglycemic activities. In a study on streptozotocin-induced hyperglycemia in mice, the chloroform fraction of ethanol extract of coix significantly reduced blood glucose as well as gluconeogenic enzyme activities; two isolated compounds, β-sitosterol and stigmasterol, have been reported as hypoglycemic agents. These findings are from animal models and in vitro experiments. Human clinical evidence for blood glucose lowering effects of coix seeds as a dietary supplement remains limited and has not been established through large, controlled human trials.
5.3 Lipid Metabolism and Anti-Obesity
Modern pharmacological studies showed that coix seed has various medicinal properties including anti-cancer, antioxidant, anti-obesity, anti-inflammatory, anti-hypertension, endocrine regulation, and cardiovascular protection. Ethanolic or water extracts of coix seed attenuated hepatic steatosis and inflammation, inhibited lipogenesis, and alleviated non-alcoholic fatty liver disease (NAFLD) along with its associated conditions in mice on a high-fat diet. Evidence in this domain is predominantly preclinical (animal models), and well-powered human trials specifically assessing coix on lipid profiles or body weight are lacking.
5.4 Anti-Inflammatory Effects
Pharmacological properties including anti-inflammatory, antioxidant, hypolipidemic, and immunomodulatory effects have garnered scientific interest. Coix seeds have an abundance of polyphenol compounds and show strong in vitro antioxidant activity, contributing to antioxidant potential. The great majority of mechanistic anti-inflammatory evidence is from in vitro (cell culture) and animal studies. Clinical (human) evidence specific to inflammation outcomes is limited.
5.5 Skin Conditions (Viral Warts)
Some studies suggest that coix seed promotes the spontaneous regression of viral infections of the skin. Meanwhile, Kanglaite, a purified oil agent used for cancer therapy, has been implied to increase the ratio of CD4+ T cells in the peripheral blood of cancer patients undergoing treatment. The immunomodulatory mechanism by which coix may influence viral wart regression has not been fully established in rigorous human trials. Traditional use for this indication is well-documented, but the clinical evidence base is small.
5.6 Gut Microbiota and Digestive Health
Numerous pharmacological effects of coix seed have been demonstrated through modern pharmacological studies, including hypoglycemia, improving liver function, anti-tumor activity, regulating intestinal microbiota, improving spleen function, and anti-inflammatory effects. In animal studies, coix seed extract treatment notably increased the diversity of gut microbiota. Human evidence specifically for gut microbiota modulation by coix seed is preliminary.
5.7 Muscle Relaxant and Skeletal Effects
Coixol (6-methoxybenzoxazolone), a pharmacologically active compound isolated from Coix lacryma-jobi L., has demonstrated central muscle relaxant properties in studies in mice and rats where coixol could decrease locomotor activity. Human clinical evidence confirming muscle relaxant effects is absent from the current published literature.
5.8 Immunomodulation
Clinical evidence from randomized clinical trials and systematic reviews showed that when used as adjunctive therapy for cancers, KLT plus chemotherapy can improve survival time, disease response rates, quality of life, and immune functions, and also reduce adverse reactions caused by chemotherapy drugs. The immune-boosting effect, as measured by T-cell subset ratios, is the area with the most clinical data, though the overall quality of this evidence base remains limited as noted above.
6. Body Systems and Associated Health Areas
- Oncology: Anti-tumor effects; adjunctive use with chemotherapy and radiotherapy for lung, liver, gastric, colorectal, pancreatic, breast, cervical, and other cancers via KLT preparation.
- Endocrine/Metabolic: Hypoglycemic effects; modulation of insulin signaling; lipid metabolism regulation; anti-obesity activity.
- Digestive System: TCM use to stimulate function of the spleen and lung, remove heat, induce diuresis, and treat diarrhea and arthritis.
- Immune System: Immunomodulation; increase of CD4+ T cell ratios in cancer patients; modulation of gut microbiota diversity.
- Musculoskeletal: Traditional use for joint stiffness, rheumatism, bi syndrome (wind-damp obstruction), and myofibrositis.
- Dermatological: Traditional and investigational use for viral skin warts; tyrosinase-inhibiting cosmetic potential of coixol.
- Renal/Urological: Diuretic and dampness-draining properties recognized in TCM; traditional use for edema and urinary difficulty.
- Hepatic: Improving liver function is one of the pharmacological effects demonstrated through modern pharmacological studies.
7. Dosage Forms and Reported Dosages
Coix is administered in multiple forms, with dose ranges varying considerably by indication and tradition.
- Traditional decoction (TCM): A typical TCM dosage is between 10–30 grams, which can be combined with water for a decoction or ground into powder. Some TCM sources report a dose range of 15–30 g, with large doses up to 60–90 g.
- Kanglaite Injection (KLTi) — clinical trials: In a randomized phase 2b trial of Kanglaite Injection plus gemcitabine for advanced pancreatic cancer, 41 patients were randomized to 30 g/day (Cohort 1) and an additional 18 to 50 g/day (Cohort 2, terminated for feasibility issues).
- Coix-seed Reactive Derivatives (CRD) — human safety study: In a clinical safety study, eight adult subjects (4 males and 4 females, ages 26.6 ± 4.7) consumed 2.0 g CRD/day for 4 weeks.
- Coix seed oil (animal toxicity study): After administering the soft capsule contents of coix seed oil at 17.4 g/(kg·day) to mice, no abnormalities were observed in general condition, food utilization rate, body weight, organ weight, organ ratio, or routine blood and biochemical indexes.
8. Safety Considerations
General Safety Profile
As a common food product and homologous TCM, Coicis Semen has remarkable medicinal effects, although there are few reports on its toxicity and adverse reactions. Tests on the acute toxicity as well as the skin and rectal irritation induced by coix seed oil showed no obvious acute toxicity in mice and suggested it is safe for oral and external use. Two studies confirmed that coix seed oil and coixan polysaccharides were safe and did not acutely induce genotoxicity through acute toxicity, bacterial reverse mutation (Ames test), bone marrow cell micronucleus, and sperm aberration testing in mice.
In the human safety study, although several laboratory data (MCHC, MCV, and serum creatinine) changed slightly, all values were within the normal range, and no severe adverse effect was observed; the results suggest that CRD intake up to 2 g/day is safe in healthy adults. The authors noted that further study is needed to define the safety of long-term administration.
Over 1 million patients in multiple countries have received Kanglaite Injection over a 20-year period without serious toxicities being reported.
Mycotoxin Contamination Risk
A specific and factually documented safety consideration involves mycotoxin contamination of commercial coix seed. Mycotoxins as secondary metabolites from microorganisms pose a potential threat to the safety of coix seed; these toxins primarily include aflatoxins (AFB1, AFB2), zearalenone (ZEN), deoxynivalenol (DON), sterigmatocystin (ST), T-2/HT-2 toxins, and ochratoxin A (OTA). Actual survey data revealed that 74% of coix seed samples were simultaneously contaminated with two or more mycotoxins. Research results indicate that long-term (20-year) consumption of coix seed may pose health risks due to contamination with ZEN or aflatoxins (AFB1/AFB2) (MOE < 10,000); particularly, when the exposure duration to ZEN exceeded 50 years, an MOE value below 100 was observed, indicating a high level of risk.
Coix seeds are susceptible to simultaneous contamination by multiple mycotoxins, which may potentially exhibit synergistic effects; from a food safety perspective, co-exposure to mycotoxins increases toxicological hazards.
Use During Pregnancy
Coix seed has historically carried precautions regarding use in pregnancy. Coix seed constituents have been reported to promote uterine contraction, which is consistent with traditional cautions against use in pregnant women. This effect has been the basis for the longstanding clinical precaution in TCM practice. The available human safety data do not include studies in pregnant women.
Drug Interactions
Formal pharmacokinetic drug-interaction studies in humans for coix seed as a dietary supplement are absent from the published literature. In the oncology context, KLT has been studied in combination with gemcitabine, platinum-based chemotherapy, EGFR-TKIs, and taxanes. KLT has diphasic broad-spectrum anti-tumor activity and has enhanced efficacy while reducing side effects in the treatment of gastric cancer, hepatocellular carcinoma, and NSCLC when combined with certain chemotherapeutic agents. These interactions are generally studied as potentially synergistic rather than adverse in the oncology literature; however, independent confirmation from high-quality trials is still required.
In Vitro Cytotoxicity
Minimal cytotoxicity (IC50 > 6 mg/mL) has been observed in L6 and 3T3-L1 cells, which highlights the relative in vitro safety of coix extracts.
9. Regulatory and Commercial Status
Coix is sold as Kanglaite in China and is classified as an anticancer drug. It was approved in China in 1995 for the treatment of advanced non-small cell lung cancer and advanced hepatocellular carcinoma. The treatment has been clinically approved in China, Russia, and has been evaluated by the U.S. Food and Drug Administration. It has been compiled in editions of the Chinese Pharmacopoeia as a traditional medicine. As a whole food and dietary supplement, coix (Job's tears grain) is widely available in Asian markets without restriction in most countries.
10. Summary of Evidence Strength
The evidence base for coix and its preparations varies significantly by indication:
- Oncology (KLT as adjunct to chemotherapy): The largest body of clinical data exists here, drawn from dozens of RCTs and multiple meta-analyses. However, independent evidence-mapping has found that three meta-analyses were of low quality, whereas 10 were critically low in quality, meaning that results suggesting improved response rates and quality of life should be interpreted with significant caution. The data are predominantly from Chinese institutions, and confirmatory high-quality multinational RCTs are lacking.
- Hypoglycemic effects: Supported by animal and in vitro data; no adequately powered human clinical trials have confirmed efficacy in glycemic control.
- Anti-inflammatory and antioxidant effects: Primarily in vitro evidence with supportive animal data; human clinical trials for these outcomes are lacking.
- Lipid metabolism / anti-obesity: Preclinical (animal) evidence only at this stage.
- Viral skin warts: Very limited human observational data; mechanistically plausible but not established.
- Musculoskeletal (traditional): Historically documented in TCM and Kampo texts; no modern rigorous clinical trials.
References
Volver